Option Care Health, Inc. (OPCH) company profile
Close on Nov 16, 2026Market cap $4.75BP/E 23.8Yield –
About Option Care Health
Services-Home Health Care Services, SIC 8082
Option Care Health, Inc. provides home and alternate-site infusion therapy services across a single operating segment. Operating under physician direction, the company supplies pharmaceuticals, complex compounded sterile solutions, and clinical care coordination to patients suffering from complex acute and chronic conditions. Key therapy areas encompass anti-infectives, clinical nutrition support, immunoglobulin treatments, chronic inflammatory and neurological disorders, bleeding disorders, heart failure, and specialized women's health regimens. Option Care Health serves patients in home environments and ambulatory suites, while contracting directly with managed care organizations, commercial third-party payers, hospitals, healthcare providers, and pharmaceutical manufacturers.
The company operates a nationwide footprint comprising 196 locations across 43 U.S. states. This delivery network includes 87 full-service pharmacies—73 of which contain ambulatory infusion suites—alongside 109 stand-alone ambulatory infusion suites, including 27 equipped with advanced practitioner capabilities. Clinical operations are supported by more than 5,000 clinicians, including pharmacists, dietitians, and approximately 2,700 employed nurses. Corporate headquarters are located in Bannockburn, Illinois.
Summary of the business section of Option Care Health's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Option Care Health, Inc.
- Headquarters
- Bannockburn, IL
- Address
- 3000 Lakeside Dr, Suite 300n 60015
- Phone
- (312) 940-2443
- Website
- optioncarehealth.com
- Employees
- 2,700, Dec 31, 2025
- Industry
- Services-Home Health Care Services
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Chicago, Illinois
Stock & identifiers
- Ticker
- OPCH
- Exchange
- Nasdaq
- IPO date
- Aug 15, 1996
- Shares outstanding
- 150M, Jul 27, 2026
- Public float
- $5.27B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 1-for-4 reverse, Feb 3, 2020; 9-for-2, Nov 6, 2019
- SEC CIK
- 1014739
- CUSIP
- 68404L201
- ISIN
- US68404L2016
- FIGI
- BBG000BQK480
- Share class FIGI
- BBG001S6X756
- LEI
- 549300DI3Q5ACSYJRI17
- EIN
- 05-0489664
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| John Charles Rademacher | Chief Executive Officer, Director | 695,152 |
| Prateek Bhatia | EVP Sp Sales & Solutions | 16,386 |
| Collin Smyser | GC & Corporate Secretary | 77,512 |
| Meenal Sethna | Chief Financial Officer | 98,337 |
| Femi Adewunmi | Chief Medical Officer | 25,314 |
| Michael Bavaro | Chief Human Resources Officer | 33,249 |
| Christopher L. Grashoff | Chief Growth Officer | 44,092 |
| Luke Whitworth | Chief Operating Officer | 169,589 |
| Nicole Maggio | Chief Accounting Officer | 28,489 |
| Michael H. Shapiro | Chief Financial Officer | 311,933 |
| R. Carter Pate | Director | 14,128 |
| Timothy P. Sullivan | Director | 82,380 |
| Harry M. Jansen Kraemer Jr | Director | 458,997 |
| Norman L. Wright | Director | 24,498 |
| Elizabeth D. Bierbower | Director | 32,871 |
| Eric Brandt | Director | 19,356 |
| Natasha Deckmann | Director | 32,002 |
| Barbara W. Bodem | Director | 21,087 |
| David W. Golding | Director | 116,525 |
| Elizabeth Quadros Betten | Director | 29,216 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $9.27M | $21.64M | $2.63M | $204 | $110 |
| FY2024 | $8.22M | -$1.87M | $2.79M | $148 | $93 |
| FY2023 | $16.61M | $22.23M | $3.65M | $215 | $92 |
| FY2022 | $6.75M | $10.07M | $1.94M | $192 | $87 |
| FY2021 | $8.42M | $13.14M | $3.29M | $182 | $109 |
| FY2020 | $1.14M | $1.14M | $1.12M | $105 | $133 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| John C. Rademacher President and Chief Executive Officer | $1.00M | $6.50M | $1.67M | $101.28K | $9.27M | +13% |
| Meenal A. Sethna Chief Financial Officer | $165.10K | $1.50M | $148.74K | – | $1.81M | – |
| Luke Whitworth Chief Operating Officer | $625.00K | $2.50M | $668.25K | $15.03K | $3.81M | +11% |
| Collin G. Smyser General Counsel and Corporate Secretary | $500.00K | $1.20M | $445.50K | $31.82K | $2.18M | +14% |
| Christopher L. Grashoff Chief Growth Officer | $407.78K | $1.08M | $331.04K | $45.85K | $1.86M | +7% |
| Michael Shapiro Former Chief Financial Officer | $521.99K | $2.50M | $469.79K | $14.00K | $3.51M | -15% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“The Company also provides nursing services to support the above therapies, comprised of its nursing team of approximately 2,700 employees, and through its network of sub-contracted nursing agencies.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?